FDA Approves Humira (adalimumab) for the Treatment of Pediatric Patients with Crohn’s Disease

NORTH CHICAGO, Ill., Sept. 25, 2014 /PRNewswire/ — AbbVie announced today that the U.S. Food and Drug Administration (FDA) has approved Humira (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in…
Drugs.com – New Drug Approvals

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us